---
author:
  - name: Sarah Knapton
    url: null
    avatar: {}
related:
  - score: 0.6444710493
    description: A powerful new class of drugs promises to change the management of heart disease for high-risk patients who struggle to get their cholesterol levels under control-a group that numbers in the millions. But only some of them are likely to get the new medicines. The new drugs are expensive.
    title: Patients Seeking Alternatives to Statins May Undergo Rigorous Vetting
    url: 'http://www.wsj.com/articles/patients-seeking-alternatives-to-statins-may-undergo-rigorous-vetting-1438029636'
    thumbnail_height: 369
    thumbnail_url: 'https://si.wsj.net/public/resources/images/BN-JO499_0727HE_G_20150727110822.jpg'
    thumbnail_width: 553
publisher:
  url: 'http://www.telegraph.co.uk'
  name: The Telegraph
  favicon: 'http://www.telegraph.co.uk/etc/designs/telegraph/core/clientlibs/themes/cars/img/favicon/icon_32x32.png'
  domain: www.telegraph.co.uk
keywords:
  - risks
  - anti-diabetes
  - drugs
  - kidney
  - blind
  - patients
  - bladder
  - found
  - increased
  - diabetes
description: 'The team of Canadian-based researchers found that compared to other anti-diabetic drugs, pioglitazone was associated with an increased risk of bladder cancer. The risk heightened with increasing duration of use and dose, they found. No increased risk was found for rosiglitazone - the drug was withdrawn from use in 2010 due to an increased risk of cardiovascular disorders, including heart attack and heart failure.'
inLanguage: en
app_links: []
isBasedOnUrl: 'http://www.telegraph.co.uk/science/2016/03/31/common-diabetes-drug-raises-risk-of-developing-cancer/'
title: Common diabetes drug raises risk of developing cancer
datePublished: '2016-03-31T20:21:01.845Z'
dateModified: '2016-03-31T20:19:03.451Z'
sourcePath: _posts/2016-03-31-common-diabetes-drug-raises-risk-of-developing-cancer.md
published: true
inFeed: true
hasPage: false
inNav: false
_context: 'http://schema.org'
_type: MediaObject

---
<article style=""><h1>Common diabetes drug raises risk of developing cancer</h1><p>The team of Canadian-based researchers found that compared to other anti-diabetic drugs, pioglitazone was associated with an increased risk of bladder cancer. The risk heightened with increasing duration of use and dose, they found. No increased risk was found for rosiglitazone - the drug was withdrawn from use in 2010 due to an increased risk of cardiovascular disorders, including heart attack and heart failure.</p><img src="http://www.telegraph.co.uk/content/dam/science/2016/03/31/diabetes_2919170b-xlarge_trans++pJliwavx4coWFCaEkEsb3kvxIt-lGGWCWqwLa_RXJU8.jpg" /></article>